SCHEMBL722312

SCHEMBL722312

COc1cc(-c2cc3nccc(-c4ccccc4-c4ccccc4)c3o2)cc(OC)c1OC

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
JAK2 O60674 4/20 0.48
JAK1 P23458 4/20 0.48
PDE4C Q08493 3/20 0.48
TYK2 P29597 3/20 0.48
KDM4E B2RXH2 1/20 0.46
ALDH1A1 P00352 1/20 0.46
HPGD P15428 1/20 0.46
PTGES O14684 1/20 0.44
ALOX5 P09917 1/20 0.44
CYP1A1 P04798 2/20 0.43
CYP1B1 Q16678 2/20 0.43
RPS6KA2 Q15349 3/20 0.42
SYK P43405 1/20 0.42
FLT1 P17948 1/20 0.42
FLT4 P35916 1/20 0.42
KDR P35968 1/20 0.42
FYN P06241 1/20 0.42
ACHE P22303 1/20 0.41
PLK1 P53350 1/20 0.41
BACE1 P56817 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL722839 0.94 PDE4C (0.51) JAK2JAK1PDE4CTYK2KDM4E
SCHEMBL724141 0.88 PDE4C (0.48) JAK2JAK1PDE4CTYK2KDM4E
SCHEMBL723790 0.87 PDE4C (0.47) JAK2JAK1PDE4CTYK2KDM4E
SCHEMBL723093 0.86 PDE4C (0.55) JAK2JAK1PDE4CTYK2KDM4E
SCHEMBL10267552 0.86 PDE4C (0.47) JAK2JAK1PDE4CTYK2KDM4E
SCHEMBL723585 0.86 PDE4C (0.51) JAK2JAK1PDE4CTYK2KDM4E
SCHEMBL10267652 0.85 CYP1A1 (0.54) JAK2JAK1PDE4CTYK2PTGES
SCHEMBL725069 0.85 PDE4C (0.46) JAK2JAK1PDE4CTYK2KDM4E
SCHEMBL724989 0.84 PDE4C (0.47) JAK2JAK1PDE4CTYK2KDM4E
SCHEMBL724908 0.83 PDE4C (0.53) JAK2JAK1PDE4CTYK2PTGES

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2609100-B1 FUROPYRIDINE DERIVATIVES MERCK PATENT GMBH (DE) 2015-06-24 EP claimed
US-9006440-B2 Furopyridine derivatives MERCK PATENT GMBH (DE) 2015-04-14 US claimed
US-20130225569-A1 FUROPYRIDINE DERIVATIVES MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2013-08-29 US claimed
EP-2609100-A2 FUROPYRIDINE DERIVATIVES Merck Patent GmbH (DE) 2013-07-03 EP claimed
WO-2012025187-A2 FUROPYRIDINE DERIVATIVES MERCK PATENT GMBH (DE) 2012-03-01 WO claimed
EP-2609100-B1 FUROPYRIDINE DERIVATIVES MERCK PATENT GMBH (DE) 2015-06-24 EP disclosed
EP-2609100-B1 FUROPYRIDINE DERIVATIVES MERCK PATENT GMBH (DE) 2015-06-24 EP disclosed
US-9006440-B2 Furopyridine derivatives MERCK PATENT GMBH (DE) 2015-04-14 US disclosed
US-9006440-B2 Furopyridine derivatives MERCK PATENT GMBH (DE) 2015-04-14 US disclosed
WO-2012025187-A2 FUROPYRIDINE DERIVATIVES MERCK PATENT GMBH (DE) 2012-03-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130225569-A1 FUROPYRIDINE DERIVATIVES SYK, FCGRT, SSB JAK2 14/4885JAK1 25/4885PDE4C 2858/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.